Cargando…
Do we still need renal biopsy in lupus nephritis?
The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to l...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918045/ https://www.ncbi.nlm.nih.gov/pubmed/27407281 http://dx.doi.org/10.5114/reum.2016.60214 |
_version_ | 1782439050517413888 |
---|---|
author | Haładyj, Ewa Cervera, Ricard |
author_facet | Haładyj, Ewa Cervera, Ricard |
author_sort | Haładyj, Ewa |
collection | PubMed |
description | The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment. |
format | Online Article Text |
id | pubmed-4918045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie |
record_format | MEDLINE/PubMed |
spelling | pubmed-49180452016-07-12 Do we still need renal biopsy in lupus nephritis? Haładyj, Ewa Cervera, Ricard Reumatologia Review Paper The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment. Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016-06-03 2016 /pmc/articles/PMC4918045/ /pubmed/27407281 http://dx.doi.org/10.5114/reum.2016.60214 Text en Copyright © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016 http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Haładyj, Ewa Cervera, Ricard Do we still need renal biopsy in lupus nephritis? |
title | Do we still need renal biopsy in lupus nephritis? |
title_full | Do we still need renal biopsy in lupus nephritis? |
title_fullStr | Do we still need renal biopsy in lupus nephritis? |
title_full_unstemmed | Do we still need renal biopsy in lupus nephritis? |
title_short | Do we still need renal biopsy in lupus nephritis? |
title_sort | do we still need renal biopsy in lupus nephritis? |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918045/ https://www.ncbi.nlm.nih.gov/pubmed/27407281 http://dx.doi.org/10.5114/reum.2016.60214 |
work_keys_str_mv | AT haładyjewa dowestillneedrenalbiopsyinlupusnephritis AT cerveraricard dowestillneedrenalbiopsyinlupusnephritis |